Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $3.72 billion. The enterprise value is $4.49 billion.
| Market Cap | 3.72B |
| Enterprise Value | 4.49B |
Important Dates
The last earnings date was Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 148.61 million shares outstanding. The number of shares has increased by 8.87% in one year.
| Shares Outstanding | 148.61M |
| Shares Change (YoY) | +8.87% |
| Shares Change (QoQ) | +2.49% |
| Owned by Insiders (%) | 1.09% |
| Owned by Institutions (%) | 108.88% |
| Float | 147.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.79 |
| Forward PS | 13.18 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.80
| Current Ratio | 1.80 |
| Quick Ratio | 1.50 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.00 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -56.90% |
| Return on Capital (ROIC) | -78.30% |
| Revenue Per Employee | $345,936 |
| Profits Per Employee | -$818,963 |
| Employee Count | 912 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0.90 |
Taxes
In the past 12 months, Insmed has paid $2.66 million in taxes.
| Income Tax | 2.66M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.56% in the last 52 weeks. The beta is 0.93, so Insmed's price volatility has been similar to the market average.
| Beta (1Y) | 0.93 |
| 52-Week Price Change | +36.56% |
| 50-Day Moving Average | 26.35 |
| 200-Day Moving Average | 26.17 |
| Relative Strength Index (RSI) | 42.56 |
| Average Volume (30 Days) | 1,762,645 |
Short Selling Information
The latest short interest is 8.53 million, so 5.74% of the outstanding shares have been sold short.
| Short Interest | 8.53M |
| Short Previous Month | 9.40M |
| Short % of Shares Out | 5.74% |
| Short % of Float | 5.80% |
| Short Ratio (days to cover) | 4.11 |
Income Statement
In the last 12 months, Insmed had revenue of $315.49 million and -$746.89 million in losses. Loss per share was -$5.23.
| Revenue | 315.49M |
| Gross Profit | 246.29M |
| Operating Income | -706.97M |
| Pretax Income | -744.23M |
| Net Income | -746.89M |
| EBITDA | -637.35M |
| EBIT | -661.50M |
| Loss Per Share | -$5.23 |
Balance Sheet
The company has $595.73 million in cash and $1.37 billion in debt, giving a net cash position of -$771.95 million or -$5.19 per share.
| Cash & Cash Equivalents | 595.73M |
| Total Debt | 1.37B |
| Net Cash | -771.95M |
| Net Cash Per Share | -$5.19 |
| Equity / Book Value | -464.81M |
| Book Value Per Share | -3.13 |
| Working Capital | 337.86M |
Cash Flow
In the last 12 months, operating cash flow was -$573.98 million and capital expenditures -$14.57 million, giving a free cash flow of -$588.55 million.
| Operating Cash Flow | -573.98M |
| Capital Expenditures | -14.57M |
| Free Cash Flow | -588.55M |
| FCF Per Share | -$3.96 |
Margins
Gross margin is 78.07%, with operating and profit margins of -224.08% and -236.74%.
| Gross Margin | 78.07% |
| Operating Margin | -224.08% |
| Pretax Margin | -235.89% |
| Profit Margin | -236.74% |
| EBITDA Margin | -202.02% |
| EBIT Margin | -209.67% |
| FCF Margin | -186.55% |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.87% |
| Shareholder Yield | -8.87% |
| Earnings Yield | -20.09% |
| FCF Yield | -15.83% |
Analyst Forecast
The average price target for Insmed is $45.29, which is 80.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.29 |
| Price Target Difference | 80.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 44.17% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Insmed has an Altman Z-Score of -4.24 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.24 |
| Piotroski F-Score | 4 |